Improving outcomes in primary CNS lymphoma. Issue 3 (September 2018)

• Record Type: Journal Article
• Authors: Graham, Maya S.; DeAngelis, Lisa M.
• Is Part Of: Baillière's best practice and research in clinical haematology. Volume 31:Issue 3(2018)
• Page Start: 262
• Page End: 269
• Publication Date: 2018-09
• Subjects: Primary central nervous system lymphoma -- Induction chemotherapy -- Consolidation chemotherapy -- Targeted therapy -- Elderly -- Primary refractory disease; Hematology -- Periodicals; Blood -- Periodicals; Hematologic Diseases -- Periodicals; Electronic journals; 616
• DOI: 10.1016/j.beha.2018.07.006
• Languages: English
• ISSNs: 1521-6926

Abstract

Abstract: Primary central nervous system lymphoma (PCNSL) is an aggressive disease with previously poor prognosis. The advent of high-dose methotrexate-based induction regimens as well as use of consolidation therapy has greatly improved this prognosis in recent decades, but durable remission still eludes half of patients. In this review, we summarize the progress made in the treatment of PCNSL as well as the challenges that remain, with a focus on defining optimal induction and consolidation regimens, including the promise of developing biotherapies. Future studies will help delineate the best combination of existing and novel treatment strategies, with the goal of expanding the cohort of patients achieving a cure.